Last reviewed · How we verify

Palmitoleic Acid + Infliximab — Competitive Intelligence Brief

Palmitoleic Acid + Infliximab (Palmitoleic Acid + Infliximab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-α inhibitor + fatty acid combination. Area: Immunology.

marketed TNF-α inhibitor + fatty acid combination TNF-α receptor (via infliximab); GPR120 and other metabolic sensors (via palmitoleic acid) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Palmitoleic Acid + Infliximab (Palmitoleic Acid + Infliximab) — Chinese Medical Association. Palmitoleic acid enhances the anti-inflammatory effects of infliximab, a TNF-α inhibitor, by modulating immune cell function and reducing systemic inflammation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Palmitoleic Acid + Infliximab TARGET Palmitoleic Acid + Infliximab Chinese Medical Association marketed TNF-α inhibitor + fatty acid combination TNF-α receptor (via infliximab); GPR120 and other metabolic sensors (via palmitoleic acid)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-α inhibitor + fatty acid combination class)

  1. Chinese Medical Association · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Palmitoleic Acid + Infliximab — Competitive Intelligence Brief. https://druglandscape.com/ci/palmitoleic-acid-infliximab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: